Literature DB >> 26758760

Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.

Robert J Motzer1, Thomas E Hutson2, Min Ren3, Corina Dutcus3, James Larkin4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26758760     DOI： 10.1016/S1470-2045(15)00543-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  33 in total

1.  Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms.

Authors:  C Rothermundt; J von Rappard; T Eisen; B Escudier; V Grünwald; J Larkin; D McDermott; J Oldenburg; C Porta; B Rini; M Schmidinger; C N Sternberg; P M Putora
Journal:  World J Urol       Date:  2016-08-03       Impact factor: 4.226

Review 2.  The Role of Circulating Tumor DNA in Renal Cell Carcinoma.

Authors:  Paulo G Bergerot; Andrew W Hahn; Cristiane Decat Bergerot; Jeremy Jones; Sumanta Kumar Pal
Journal:  Curr Treat Options Oncol       Date:  2018-02-20

Review 3.  [TKI 2.0 - changes in the medical treatment of renal cell carcinoma].

Authors:  V Stühler; S Kruck; M Hegemann; M Notohamiprodjo; T Todenhöfer; N Kröger; A Stenzl; J Bedke
Journal:  Urologe A       Date:  2018-03       Impact factor: 0.639

Review 4.  Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.

Authors:  Margaret E Gatti-Mays; Jason M Redman; Julie M Collins; Marijo Bilusic
Journal:  Hum Vaccin Immunother       Date:  2017-08-31       Impact factor: 3.452

Review 5.  Immunotherapy of advanced renal cell carcinoma: Current and future therapies.

Authors:  David Gill; Andrew W Hahn; Guru Sonpavde; Neeraj Agarwal
Journal:  Hum Vaccin Immunother       Date:  2016-08-05       Impact factor: 3.452

Review 6.  An overview of rapamycin: from discovery to future perspectives.

Authors:  Young Ji Yoo; Hanseong Kim; Sung Ryeol Park; Yeo Joon Yoon
Journal:  J Ind Microbiol Biotechnol       Date:  2016-09-09       Impact factor: 3.346

Review 7.  Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.

Authors:  Nizar M Tannir; Sumanta K Pal; Michael B Atkins
Journal:  Oncologist       Date:  2018-02-27

8.  Combination therapy for metastatic renal cell carcinoma.

Authors:  Carlo Buonerba; Giuseppe Di Lorenzo; Guru Sonpavde
Journal:  Ann Transl Med       Date:  2016-03

Review 9.  Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.

Authors:  Peter Makhov; Shreyas Joshi; Pooja Ghatalia; Alexander Kutikov; Robert G Uzzo; Vladimir M Kolenko
Journal:  Mol Cancer Ther       Date:  2018-07       Impact factor: 6.261

10.  A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.

Authors:  Martin H Voss; Rupal S Bhatt; Nicholas J Vogelzang; Mayer Fishman; Robert S Alter; Brian I Rini; J Thaddeus Beck; Monika Joshi; Ralph Hauke; Michael B Atkins; Earle Burgess; Theodore F Logan; David Shaffer; Rahul Parikh; Nauman Moazzam; Xiaosha Zhang; Chad Glasser; Matthew L Sherman; Elizabeth R Plimack
Journal:  Cancer       Date:  2019-04-05       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.